NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/28/24
NovoCure device slows spread of lung cancer to brain in late-stage study; shares riseProactive Investors • 03/27/24
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerBusiness Wire • 03/27/24
Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer TreatmentInvestors Business Daily • 03/27/24
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerBusiness Wire • 03/27/24
Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect?Zacks Investment Research • 03/13/24
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGOBusiness Wire • 03/11/24
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateBusiness Wire • 02/22/24
Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength?Zacks Investment Research • 01/19/24
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung CancerBusiness Wire • 01/18/24
Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should KnowZacks Investment Research • 01/11/24
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed GlioblastomaBusiness Wire • 01/09/24
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company UpdateBusiness Wire • 01/08/24
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to ProfitabilityBusiness Wire • 11/28/23